使用易布鲁丁尼布成功治疗与慢性淋巴细胞白血病相关的单克隆性免疫性状细胞瘤病变
Ayano Saito1, Yoshihiro Kameoka1, Kumi Ubukawa2
1Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Internal medicine (Tokyo, Japan)
|October 6, 2024
概括
一名患有慢性淋巴细胞白血病的患者通过使用针对单克隆性免疫性球瘤病的向疗法 - - 伊布鲁替尼 (ibrutinib) 实现了脏综合征的完全缓解. 这标志着这种罕见的脏疾病的新型治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 单克隆性免疫性囊病 (mITG) 是一种罕见的病,其特点是质沉积物,通常与血液状况有关.
- 性综合征可能是慢性淋巴细胞白血病 (CLL) 的并发症.
- 对mITG的标准治疗通常涉及免疫抑制疗法和化疗.
研究的目的:
- 在患有CLL的患者中报告mITG的二次性瘤综合征病例.
- 评估ibrutinib的疗效,一个布鲁顿氨酸激酶抑制剂,在治疗与CLL相关的mITG.
- 为了突出一个新的治疗策略mITG.
主要方法:
- 一名71岁的女性患者患有CLL和新诊断的脏综合征接受了脏活检.
- 活检揭示了IgG1-lambda阳性单克隆性免疫细胞质细胞瘤病变 (mITG).
- 该患者接受了IBRUTINIB治疗,并且对功能进行了24个月的监测.
主要成果:
- 患者在24个月的易布鲁替尼治疗后实现了完全的缓解.
- 易布鲁替尼在解决由mITG引起的性综合征方面表现出显著的疗效.
- 这是第一次报告使用ibrutinib治疗mITG的病例.
结论:
- 易布鲁替尼可以作为慢性淋巴细胞白血病患者单克隆性免疫性球病的有效治疗方法.
- 使用布鲁顿氨酸激酶抑制剂的向治疗为管理与血液恶性瘤相关的罕见脏疾病提供了新的途径.
- 需要进一步的研究来探索ibrutinib在mITG中的作用.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:27Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K